Sanofi: collaboration with Innovent Biologics in China

(CercleFinance.com) - Sanofi announces that it is collaborating with Innovent Biologics, a company that has a large footprint in China, to bring innovative medicines to patients with hard-to-treat cancers in the country.


They are committed to further developing and commercialising two of Sanofi's lead oncology assets that are currently in clinical trials, SAR408701 and SAR444245, in combination with sintilimab, the leading immune checkpoint inhibitor in China.

In addition to this collaboration and licensing agreement, and subject to antitrust approval and customary conditions, Sanofi will initially invest 300 million euros in Innovent's capital through the subscription of new shares.



Copyright (c) 2022 CercleFinance.com. All rights reserved.